← FDA DRUG APPROVALS

FDA ANDA · ANDA062984

OXACILLIN SODIUM

Sponsor: WATSON LABS INC

APPLICATION
ANDA062984
TYPE
ANDA
ORIGINAL APPROVAL
1988-09-29
LATEST ACTION
2016-04-04
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

OXACILLIN SODIUMDiscontinued
OXACILLIN SODIUM EQ 10GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2016-04-04Labeling · Supplement 17 · standardAP
2000-12-08Manufacturing (CMC) · Supplement 16AP
1999-05-14Manufacturing (CMC) · Supplement 15AP
1998-09-29Manufacturing (CMC) · Supplement 14AP
1997-12-22Manufacturing (CMC) · Supplement 13AP
1997-07-22Labeling · Supplement 11AP
1995-02-10Manufacturing (CMC) · Supplement 10AP
1995-01-27Manufacturing (CMC) · Supplement 9AP
1994-03-18Labeling · Supplement 3AP
1994-01-13Manufacturing (CMC) · Supplement 8AP
1993-11-19Manufacturing (CMC) · Supplement 6AP
1993-11-19Manufacturing (CMC) · Supplement 7AP
1992-03-11Manufacturing (CMC) · Supplement 4AP
1990-11-09Manufacturing (CMC) · Supplement 2AP
1988-12-07Manufacturing (CMC) · Supplement 1AP
1988-09-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →